Monzo-Gallo, Patricia
Alastruey-Izquierdo, Ana
Chumbita, Mariana
Aiello, Tommaso Francesco
Gallardo-Pizarro, Antonio
Peyrony, Olivier
Teijon-Lumbreras, Christian
Alcazar-Fuoli, Laura
Espasa, Mateu
Soriano, Alex
Marco, Francesc
Garcia-Vidal, Carolina
Funding for this research was provided by:
Agència de Gestió d'Ajuts Universitaris i de Recerca (SGR 01324 Q5856414G)
Instituto de Salud Carlos III (PI21/01640)
Universitat de Barcelona
Article History
Received: 19 January 2024
Accepted: 12 March 2024
First Online: 27 May 2024
Declarations
:
: CG-V has received honoraria for talks on behalf of Gilead Science, Merck Sharp and Dohme, Pfizer, Jannsen, Novartis, Lilly, and a grant support from Gilead Science and Merck Sharp and Dohme. AS has received honoraria for talks on behalf of Merck Sharp and Dohme, Pfizer, Novartis, Angelini, as well as grant support from Pfizer. OP has received honoraria for talks on behalf of MSD and Qiagen, and expertise for Sanofi. PM-G has received honoraria for talks on behalf of Pfizer.
: Informed consent was obtained from all individual participants included in the study.
: All participants have consented to the submission of the brief report to the journal.